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191disease progression. Our recent ﬁndings that endocannabi-
noid receptors and enzymes are signiﬁcantly altered in the
post-mortem cerebellum of patients aﬀected by autosomal-
dominant hereditary ataxias suggest that targeting the
endocannabinoid signaling system may be a promising
therapeutic option. Our goal was to investigate the status
of the endocannabinoid signaling system in a transgenic
mouse model of SCA-3, in the two CNS structures most
aﬀected in this disease – cerebellum and brainstem. These
animals exhibited progressive motor incoordination, imbal-
ance, abnormal gait, muscle weakness, and dystonia, in par-
allel to reduced in vivo brain glucose metabolism,
deterioration of speciﬁc neuron subsets located in the den-
tate nucleus and pontine nuclei, small changes in microglial
morphology, and reduction in glial glutamate transporters.
Concerning the endocannabinoid signaling, our data indi-
cated no changes in CB2 receptors. By contrast, CB1 recep-
tors increased in the Purkinje cell layer, in particular in
terminals of basket cells, but they were reduced in the den-
tate nucleus. We also measured the levels of endocannabi-
noid lipids and found reductions in anandamide and
oleoylethanolamide in the brainstem. These changes corre-
lated with an increase in the FAAH enzyme in the brainstem,
which also occurred in some cerebellar areas, whereas
other endocannabinoid-related enzymes were not altered.
Collectively, our results in SCA-3 mutant mice conﬁrm a
possible dysregulation in the endocannabinoid system in
the most important brain structures aﬀected in this type of
ataxia, suggesting that a pharmacological manipulation
addressed to correct these changes could be a promising
option in SCA-3.  2016 IBRO. Published by Elsevier Ltd.
All rights reserved.
Key words: cannabinoids, endocannabinoid signaling sys-
tem, autosomal-dominant inherited ataxias, spinocerebellar
ataxia-3, Machado-Joseph disease, motor incoordination.
INTRODUCTION
Autosomal-dominant spinocerebellar ataxias (SCAs) are
a group of inherited neurodegenerative disorders, in
which the most prevalent cases belong to the family of
polyglutaminopathies (polyQ), that also includes
Huntington’s disease (Durr, 2010; Klockgether, 2011;
Seidel et al., 2012; Ru¨b et al., 2013). The most prevalent
type within SCAs is SCA-3 or Machado-Joseph disease,
which is caused by a polyglutamine expansion in a protein
identiﬁed in the disease and called ataxin-3 (Paulson,
2012). The key neuropathological hallmark in SCA-3,
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clear inclusions, which are linked to protein misfolding,
failed or incomplete proteolysis, and deposition and for-
mation of protein aggregates (Paulson, 2012). This is a
key point in SCA-3 given the role of normal ataxin-3 in
the control of ubiquitination/ deubiquitination balance
(Ru¨b et al., 2013). These aggregates are thought to con-
tribute to the pathogenic process by eliciting transcrip-
tional dysregulation, but also mitochondrial failure,
excitotoxicity, altered calcium homeostasis, oxidative
stress and local inﬂammatory events (Matilla-Duen˜as
et al., 2012; Orr, 2012), which are ultimately responsible
of the death of speciﬁc neuronal subpopulations located
in some central nervous system (CNS) structures, mainly
the cerebellum, the brainstem and the striatum (Taroni
and DiDonato, 2004; Fratkin and Vig, 2012; Matilla-
Duen˜as, 2012). This speciﬁcity in neuronal death occurs
despite the ubiquitous expression of mutant ataxin-3
and explains that, clinically, patients present a broad-
spectrum of neurological abnormalities, which include pri-
mary cerebellar symptoms, such as progressive loss of
motor coordination and gait anomalies (Riess et al.,
2008; Matilla-Duen˜as, 2012), and non-cerebellar symp-
toms such as peripheral amyotrophy (muscle atrophy),
oculomotor impairment, spasticity and extrapyramidal
signs, e.g. rigidity and dystonia, typically found at
advanced phases but also present at earlier stages
(Matilla-Duen˜as et al., 2012; Jacobi et al., 2013; Ru¨b
et al., 2013).
The disease has no cure and also lacks eﬀective
treatments that alleviate major symptoms or modify
disease progression (Ru¨b et al., 2013), although several
strategies are under investigation including: (i) inhibitors
of histone deacetylases (e.g. sodium butyrate (Chou
et al., 2011)) to correct transcriptional dysregulation; (ii)
interference RNA to reduce the translation of the mutated
protein (Alves et al., 2010); and (iii) activation of autop-
hagy to eliminate protein aggregates (Menzies et al.,
2010; Nascimento-Ferreira et al., 2013; Silva-Fernandes
et al., 2014). Compared to Huntington’s disease, the most
prevalent polyQ disorder, which has been investigated for
the possible beneﬁts of cannabinoid-based therapies as
disease modiﬁers (recently reviewed in (Ferna´ndez-Ruiz
et al., 2015)), SCA-3 and the other autosomal-dominant
inherited ataxias have not been investigated yet for this
possibility, despite the well-demonstrated neuroprotective
eﬀects of these compounds (Ferna´ndez-Ruiz et al., 2010,
2011, 2015). Only two studies conducted in our laboratory
have recently addressed the status of endocannabinoid
receptors and enzymes in the post-mortem cerebellum
of SCA patients (Rodrı´guez-Cueto et al., 2014a,b). One
of these studies described that CB1 and CB2 receptors
become up-regulated in SCA patients (Rodrı´guez-Cueto
et al., 2014a). This includes the overexpression of both
receptors in neuronal subpopulations in which they are
not usually located or their expression is too weak, i.e.
Purkinje cells (Rodrı´guez-Cueto et al., 2014a). Both
receptors, but particularly the CB2 receptors, were also
found in glial elements, e.g. reactive microglia, macro-
phages and astrocytes, in control subjects experiencing
a signiﬁcant elevation in the case of SCA patients(Rodrı´guez-Cueto et al., 2014a). The fact that the two
major receptors for endocannabinoids are altered in
SCA patients supports the idea that those cannabinoids
selectively targeting the CB1 (they are eﬀective in reduc-
ing excitotoxicity (Ferna´ndez-Ruiz et al., 2010, 2011))
and/or the CB2 receptor (they are active on glial activation
and associated local inﬂammatory events (Ferna´ndez-
Ruiz et al., 2007, 2010)) may be possibly beneﬁcial in
SCAs. These eﬀects may be reinforced by other neuro-
protective properties of cannabinoids, for example, their
activity against oxidative injury, their capability to act on
several transcription factors (e.g. Nrf-2, NFjB) or to bind
the peroxisome-proliferator activating receptors (PPARs),
all of them already demonstrated in numerous chronic
neurodegenerative disorders (Ferna´ndez-Ruiz et al.,
2010, 2013). In a further study (Rodrı´guez-Cueto et al.,
2014b), we analyzed endocannabinoid-inactivating
enzymes, e.g. fatty acid amide hydrolase (FAAH),
monoacyl-glycerol lipase (MAGL). We were able to detect
immunoreactivity for the FAAH and MAGL enzymes in the
granular layer, Purkinje cells, neurons of the dentate
nucleus and areas of white matter in the cerebellum of
patients at levels notably higher than control subjects,
and, using double-labeling procedures, we found
co-localization of FAAH and MAGL with calbindin,
supporting the presence of these enzymes in Purkinje
neurons (Rodrı´guez-Cueto et al., 2014b). The interest of
these two enzymes is that they are also susceptible to
be pharmacologically manipulated, so that their inhibitors
may become in potential disease-modifying therapies in
these disorders. Indirect support to the therapeutic
potential of the endocannabinoid system in SCAs comes
from studies identifying mutations in a/b-hydrolase
domain-containing 12 (ABHD12) gene, which encodes
an enzyme also involved in endocannabinoid catabolism
(Fiskerstrand et al., 2010; Chen et al., 2013). Such
mutations have been related to a clinical phenotype that
includes ataxia (associated with cerebellar atrophy) and
ocular abnormalities, although with variable occurrence
and extent (Fiskerstrand et al., 2010; Chen et al., 2013).
In addition, the genetic ablation of this enzyme in mice
was associated with the development of ataxia and mus-
cle weakness, accompanied by microglial activation in
numerous CNS structures (Blankman et al., 2013).
The problem with the changes found in the
endocannabinoid signaling in post-mortem tissues from
SCA patients is that they correspond to a very
advanced stage of the disease, when patients died, and
it is unclear whether they also exist (or are diﬀerent)
during the diﬀerent stages in the disease progression
(e.g. presymptomatic, early symptomatic or stable
symptomatic stages). To clarify this question would be
critical to elucidate, for example, whether the changes in
endocannabinoid signals may be part of the pathogenic
process. Therefore, the issue would need to be
investigated in experimental models of SCA-3, or other
autosomal-dominant inherited ataxias, as a necessary
step for the design of reliable future cannabinoid-based
therapies. Such studies do not exist to date, in part due
to the lack of useful models of these disorders. In this
respect, a transgenic mouse model of SCA-3 has been
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neurological and neuropathological signs of the disease,
following a gradual and progressive pattern with
expression of mutant ataxin-3 at near endogenous
levels (Silva-Fernandes et al., 2014). We have used these
mice for investigating the changes in the endocannabi-
noid signaling in key CNS structures related to the symp-
toms and neuropathological lesions observed in SCA-3.
We ﬁrst characterized the progression of neurological def-
icits in these mice using diﬀerent behavioral tests useful to
detect anomalies in motor coordination, balance, motor
strength and dystonia (e.g. rotarod, balance beam, hang-
ing wire, clasping, footprinting), and we correlated these
changes with diﬀerent neuropathological signs reﬂecting
neuronal malfunctioning or death in these CNS structures.
With these neurological and neuropathological data, we
deﬁned three diﬀerent stages for this study: (i) a presymp-
tomatic/early symptomatic stage (up to 16 weeks); (ii) a
stable symptomatic stage (up to 32 weeks); and (iii) an
advanced stage (up to 56 weeks and later on), in which
we recorded the changes in endocannabinoid ligands
and related signaling lipids, and their receptors and
enzymes, using diﬀerent biochemical and histological
approaches, and concentrating in the two key CNS struc-
tures (cerebellum, brainstem) aﬀected in the disease
(Fratkin and Vig, 2012; Seidel et al., 2016).EXPERIMENTAL PROCEDURES
Animals and sampling
All experiments were conducted with pCMVMJD135Q
transgenic and non-transgenic littermate sibling mice
bred in our animal facilities from initial breeders
provided by Patricia Maciel (University of Minho, Braga,
Portugal; Silva-Fernandes et al., 2014). Oﬀspring were
genotyped for the transgene containing the ataxin-3 muta-
tion (around 135Q) following the procedure described pre-
viously (Silva-Fernandes et al., 2014). All animals were
housed in a room with controlled photoperiod (08:00–
20:00 light) and temperature (22 ± 1 C) with free access
to standard food and water. All experiments were con-
ducted according to local and European rules (directive
2010/63/EU), followed the ARRIVE guidelines and were
approved by the ‘‘Comite´ de Experimentacio´n Animal” of
our university (ref. CEA-UCM 56/2012). We used non-
transgenic and pCMVMJD135Q transgenic male mice
for longitudinal studies aimed ﬁrst at characterizing the
appearance of the pathological phenotype at behavioral,
biochemical and histological levels, and second to ana-
lyze a possible dysregulation in the endocannabinoid sig-
naling. A series of behavioral tests to identify deﬁcits in
motor coordination and balance, and motor weakness
and/or dystonia, were employed always with at least six
animals per experimental condition (genotype and age).
This included hanging wire, balance beam, footprinting
and rotarod tests, and analysis of clasping behavior which
is a marker of dystonia. Behavioral analyses were per-
formed within 7–55 weeks after birth, which allowed for
the establishment of three diﬀerent disease stages: (i) a
presymptomatic/early symptomatic stage that included
animals up to 16 weeks after birth, which, in agreementwith previous studies (Silva-Fernandes et al., 2014),
was characterized by loss of muscle strength in the hang-
ing wire test; (ii) a stable symptomatic stage that included
animals up to the age of 32 weeks after birth, which
included impaired performance in the balance beam and
the rotarod, indicating problems of balance and motor
coordination, as also seen previously (Silva-Fernandes
et al., 2014); and (iii) an advanced stage at ages up to
56 weeks after birth that included signiﬁcant deﬁciencies
in gait and dystonia, reﬂected in a worsened performance
in the footprinting tests and the occurrence of clasping
behavior, respectively. During this period, animals were
also subjected at two ages (21 and 43 weeks after birth)
to an in vivo analysis of glucose utilization in the CNS
using a PET procedure.
Immediately after the last behavioral recording, some
of the animals were transcardially perfused with saline
followed by fresh 4% paraformaldehyde in 0.1 M
phosphate buﬀered-saline (PBS), pH 7.4, and their brain
was collected and post-ﬁxed for one day at 4 C, then
immersed in 30% of sucrose solution for another day,
and ﬁnally stored at 80 C for Nissl staining and
immunohistochemical analysis. In other mice, brains
were collected and the cerebellum and brainstem were
dissected and rapidly frozen in dry ice, and stored at
80 C for biochemical analysis (qRT-PCR and Western
blotting), as well as for analysis of endocannabinoid
concentrations. In all cases, the animal weight was
recorded during the whole period of disease
progression. This also included the examination of the
animal physical appearance which allowed detecting, for
example, the occurrence of kyphosis at the advanced
stages. A separate group of wild-type and
pCMVMJD135Q transgenic male mice were used to
quantify animal survival using Kaplan–Meier analysis. In
most of experiments, a range of 6–8 animals were used
per experimental group.
Behavioral recordingRotarod test. We used a LE8200 device (Panlab,
Barcelona, Spain). After a period of acclimation and
training (ﬁrst session: 0 rpm for 30 s; second and third
sessions: 4 rpm for 60 s, with periods of 10 min between
sessions) conducted 30 min before, animals were tested
with an acceleration from 4 to 40 rpm over a period of
300 s. Mice were tested for three consecutive trials with
a rest period of approximately 15 min between trials and
the mean of three trials was calculated.
Hanging wire test. Mice were placed on a wire cage
top, which was slowly inverted and suspended at
approximately 30 cm to the ﬂoor. The latency by each
animal to fall from the cage top was recorded. The
process was repeated three times and the mean of the
three trials calculated.
Balance beam. Motor coordination and balance were
assessed by measuring the ability of the mice to stay
upright and walk across an elevated 10-mm round
diameter wood beam. The test was performed over two
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testing. The time spent by each animal to travel a distance
of 80 cm in the beam was recorded. The process was
repeated three times and the mean of the three trials
calculated.
Footprinting test. To detect abnormalities in gait, front
and hind paws were dipped in red and blue water-based
dye, respectively. Mice were then placed on a sheet of
white paper and allowed to walk through a tunnel,
leaving their footprint pattern on the white paper.
Hindlimb clasping. Mice were suspended by the tail, so
that their body dangled in the air facing downward.
Hindlimb position was observed with the mice lifted by
the tail for 30 s and animals were scored according to the
following scale: (i) score = 0 if the hindlimbs are
consistently splayed outward, away from the abdomen;
(ii) score = 1 if one hindlimb is retracted toward the
abdomen; (iii) score = 2 if both hindlimbs are partially
retracted toward the abdomen; and (iv) score = 3 if both
hindlimbs are entirely retracted and touching the abdomen.
In vivo analysis of glucose metabolism: [18F]FDG PET
imaging
To evaluate the regional brain metabolic activity, PET with
the radiotracer [18F]FDG was performed. Brieﬂy, mice
were fasted, to minimize the inﬂuence of glucemia, for
at least 12 h previous to be i.p. injected with
approximately 11.1 MBq of [18F]FDG (Instituto
Tecnolo´gico PET, Madrid, Spain). After an uptake
period of 45 min, mice were scanned with a small-
animal hybrid PET/CT (computed tomography) device
(Albira ARS scanner, Oncovision, Valencia, Spain)
under 2% isoﬂurane anesthesia. PET acquisition time
was 30 min and it was immediately followed by CT
scanning. After reconstruction of the PET and CT
images, these were co-registered to a magnetic
resonance image (MRI) template for the mouse brain, in
which the brain regions were delineated. To this aim,
the CT image was ﬁrst co-registered to the MRI
template and the mathematical transformation was
saved. Then, this transformation was applied to its own
fused PET image. This step allows the right matching of
the PET image with the mouse brain MRI template. All
these steps were carried out using PMOD 3.0 software
(PMOD Technologies Ltd., Zurich, Switzerland). As
index of regional metabolic activity, we used the
standard uptake value (SUV), which is currently the
most used quantiﬁcation index using [18F]FDG PET
imaging for small animals (Deleye et al., 2014). It repre-
sents the ratio of the regional radioactivity concentration
measured by the PET scanner and the actual injected
dose (corrected for radiotracer decay at the time of the
injection) divided by the body weight of the animal.
Biochemical analysesReal-time qRT-PCR analysis. Total RNA was
extracted using SurePrepTM RNA/Protein Puriﬁcation kit(Fisher BioReagents, Fair Lawn, NJ, USA). The total
amount of RNA was quantitated by spectrometry at
260 nm and its purity was evaluated by the ratio between
the absorbance values at 260 and 280 nm, whereas its
integrity was conﬁrmed in agarose gels. To prevent
genomic DNA contamination, DNA was removed and
single-stranded complementary DNA was synthesized
from 1 lg of total RNA using a commercial kit (Rneasy
Mini Quantitect Reverse Transcription, Qiagen, Izasa,
Madrid, Spain). The reaction mixture was kept frozen at
20 C until enzymatic ampliﬁcation. Quantitative
real-time PCR assays were performed using TaqMan
Gene Expression Assays (Applied Biosystems, Foster
City, CA, USA) to quantify mRNA levels for CB1
receptor (ref. Mm00432621_s1), CB2 receptor (ref.
Mm00438286_m1), FAAH (ref. Mm00515684_m1),
MAGL (ref. Mm00449274_m1), DAGL (ref.
Mm00813830_m1), NAPE-PLD (ref. Mm00724596_m1),
calbindin (ref. Mm00486647_m1), NSE (ref.
Mm00469062_m1), BDNF (ref. Mm01334042_m1), IL-1b
(ref. Mm00434228_m1), TNF-a (ref. Mm99999068_m1),
GLAST (ref. Mm00600697_m1) and GLT-1 (ref.
Mm00441457_m1) using GAPDH expression (ref.
Mm99999915_g1) as an endogenous control gene for
normalization. The PCR assay was performed using the
7300 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA) and the threshold cycle (Ct) was
calculated by the instrument’s software (7300 Fast
System, Applied Biosystems, Foster City, CA, USA).Western blot analysis. Puriﬁed protein fractions were
isolated using SurePrepTM RNA/Protein Puriﬁcation kit
(Fisher BioReagents, Fair Lawn, NJ, USA).
Subsequently, 20 lg of protein was boiled for 5 min in
Laemmli SDS loading buﬀer (10% glycerol, 5% SDS,
5% b-mercaptoethanol, 0.01% bromophenol blue and
125 mM TRIS–HCl, at pH 6.8) and loaded onto a 12%
acrylamide gel (Bio-Rad Laboratories, Hercules, CA,
USA), and then transferred to a PVDF membrane
(Immobilon-P, Millipore, Bedford, MA, USA) using mini
Trans-Blot Electrophoretic transfer cell (Bio-Rad
Laboratories, Hercules, CA, USA). Membranes were
blocked with 5% non-fat milk and incubated overnight at
4 C with the antibodies indicated in Table 1, followed
by a second incubation during 2 h at room temperature
with an ECLTM Horseradish Peroxidase-linked whole
secondary antibody (GE Healthcare UK Limited,
Buckinghamshire, UK) at a 1:5000 dilution. Reactive
bands were detected by chemiluminescence with the
AmershamTM ECLTM Prime Western Blotting Detection
Reagent (GE Healthcare UK Limited, Buckinghamshire,
UK). Images were analyzed on a ChemiDoc station with
Quantity one software (Bio-Rad Laboratories, Madrid,
Spain). Data were calculated as the ratio between the
optical densities of the speciﬁc protein band and the
housekeeping protein GAPDH, and they were
normalized as percentages over the control group for
presentation.LC/MS analysis for endocannabinoid levels. The
amounts of endocannabinoids and related
Table 1. List of antibodies used in Western blotting or immunohistochemical analyses (WB: Western blotting; IHC: immunohistochemistry)
ANTIBODY DILUTION (IHC) DILUTION (WB) CLASS MANUFACTURER
anti-CB1: Rb-Af380 1:500 1:300 Polyclonal Frontier Institute, Hokkaido, Japan
anti-FAAH:sc-26427 1:200 1:200 Polyclonal Santa Cruz Biotechnology, CA, USA
anti-calbindin D-28 K:AB1778 1:250 1:500 Polyclonal Millipore, Billerica, MA, USA
anti- ataxin-3: MAB5360 1:500 Polyclonal Millipore, Billerica, MA, USA
anti-polyQ:MAB1574 1:500 Monoclonal Millipore, Billerica, MA, USA
anti-GAPDH:G8795 1:5000 Monoclonal Sigma Chem., Madrid, Spain
anti-GFAP:Z0334 1:500 Polyclonal DakoCytomation, Glostrup, Denmark
anti-Iba1:019–19741 1:300 Polyclonal Wako, Osaka, Japan
anti-ubiquitin:Z0458 1:200 Polyclonal DakoCytomation, Glostrup, Denmark
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determined by liquid chromatography-atmospheric
pressure chemical ionization-mass spectrometry
(LC/MS; 1100 LC-MSD, SL model; Agilent Technologies
Inc., Wilmington, DE, USA). The protocol used was
described previously (Patel et al., 2003) with slight modi-
ﬁcations. Tissue samples were weighed and placed into
borosilicate glass tubes containing 2 ml of acetonitrile with
84 pmol of [2H8]AEA and 186 pmol of [
2H8]2-AG (Cayman
Chemical, Ann Arbor, MI, USA). Tissues were homoge-
nized with a glass rod and sonicated for 60 min. Samples
were incubated overnight at 20 C to precipitate pro-
teins. Samples were centrifuged at 1500g for 3 min, and
supernatants were removed to a new glass tube and
evaporated to dryness under nitrogen. The samples were
resuspended in methanol (300 ll) to recapture any lipids
adhering to the glass tube, and dried again. Finally, lipid
extracts were suspended in 30 ll of methanol, 5 ll of
which were used for the LC/MS analysis. Samples were
separated on a reverse-phase C18 column (Kromasil,
250  2 mm, 5-lm diameter) using mobile phase A
(deionized water with 1 mM ammonium acetate and
0.005% acetic acid) and mobile phase B (methanol with
1 mM ammonium acetate, and 0.005% acetic acid). Sam-
ples were eluted at a ﬂow rate of 300 ll/min by a linear
gradient. The percentage of solvent B increased linearly
from 85% to 100% in 25 min then held at 100% solvent
B for 10 min. Over the next 10 min, solvent B decreased
linearly from 100 to 85% and was held at 85% for an addi-
tional period of 10 min. MS detection was carried out in
the selected ion monitoring mode using m/z values to
detect [2H8]AEA (m/z 356), AEA (m/z 348), [
2H8]2-AG
and 1(3)-AG (m/z 387), 2-AG and 1(3)-AG (m/z 379),
PEA (m/z 299), OEA (m/z 326) and 2-OG and 1(3)-OG
(m/z 357). As 2-AG and 2-OG are usually observed as
doublets because of isomerization to the 1,3 form during
extraction (Patel et al., 2003), the area of both peaks were
combined to yield total 2-AG or 2-OG. To calibrate the
system, standard curves for the AEA, PEA, OEA, 2-AG
and 2-OG (Cayman Chemical, Ann Arbor, MI, USA) were
used. Each endocannabinoid concentration in the
diﬀerent samples was calculated by comparison with the
corresponding deuterated internal standard: [2H8]AEA
for calculating AEA, PEA and OEA levels, and
[2H8]2-AG in the case of 2-AG and 2-OG. The amounts
of endocannabinoids and related N-acylethanolamines
and 2-acylglycerols calculated were normalized to wet
tissue weight and expressed as % over the control group
for presentation.Histological proceduresTissue slicing. Fixed brains were sliced with a cryostat
to obtain sagittal sections (30 lm thick), including the two
areas under investigation, that were collected on gelatin-
coated slides. Sections were used for procedures of
Nissl-staining or immunohistochemistry.Nissl staining. The frozen brain sagittal sections were
incubated with a solution of methylene blue 0.1% for
5 min and washed with distilled water. The samples
were dehydrated, sealed and coverslipped with non-
aqueous mounting medium. A Leica DMRB microscope
(Leica, Wetzlar, Germany) and a DFC300FX camera
(Leica) were used for the observation and photography
of the slides, respectively. For counting the number of
Nissl-stained cells, high resolution photomicrographs
were taken with the 20x objective under the same
conditions of light, brightness and contrast. Four images
coming from at least three sections per animal were
analyzed. The ﬁnal value for each group is the mean for
all animals included in the study. Data are expressed as
percentage over the wild-type group.Immunohistochemistry. Slices were preincubated for
20 min in 0.1 M PBS with 0.1% Triton X-100, pH 7.4,
and subjected to endogenous peroxidase blockade by
incubation for 1 h at room temperature in peroxidase
blocking solution (Dako Cytomation, Glostrup,
Denmark). After incubation with the corresponding
primary antibody (see details of the diﬀerent antibodies
used and their conditions in Table 1) in 0.1 M PBS with
0.01% Triton X-100, pH 7.4, overnight at 4 C, sections
were washed in 0.1 M PBS and incubated for 2 h at
room temperature with the appropriate biotin-conjugated
anti-goat or anti-rabbit secondary antibodies (1:200;
Vector Laboratories, Burlingame, CA, USA). Avidin–
biotin complex (Vectastain Elite ABC kit; Vector
Laboratories, Burlingame, CA, USA) and a DAB
substrate–chromogen system (Dako Cytomation,
Glostrup, Denmark) were used to obtain a visible
reaction product. Negative control sections were
obtained using the same protocol with omission of the
primary antibody. All sections for each
immunohistochemical procedure were processed at the
same time and under the same conditions. A Leica
DMRB microscope and a Leica DFC300FX camera
196 C. Rodrı´guez-Cueto et al. / Neuroscience 339 (2016) 191–209(Leica, Wetzlar, Germany) were used for slide
observation and photography.
Statistics
Data were assessed by unpaired Student’s t-test or two-
way ANOVA for repeated measures followed by the
Bonferroni test, as required, using the GraphPad
software (version 5.0). The Long Rank method was
used for the analysis of Kaplan–Meier curves.
RESULTS
Characterization of the pathological phenotype in
SCA-3 transgenic mice
This study was initiated before the ﬁrst report with the
neurological and neuropathological characterization of
these SCA-3 transgenic mice was published (Silva-
Fernandes et al., 2014), so we ﬁrst characterized the mice
with a threefold purpose: (i) to conﬁrm that, in our hands,
animals developed a pathological phenotype reminiscent
of SCA-3; (ii) to establish the best stages in the disease
progression during which to investigate the changes in
the endocannabinoid signaling; and (iii) to determine the
most-aﬀected CNS structures in which this should be
investigated. We found, using western blotting, expres-
sion of human ataxin-3 only in transgenic mice in contrast
with the expression of mouse ataxin-3 in both wild-type
and SCA-3 transgenic mice (Fig. 1A). We also conﬁrmed
by western blotting, using an anti-polyglutamine antibody,
that polyQ expansions were only evident in SCA-3 trans-
genic mice (Fig. 1B). In agreement with the data pub-
lished by Silva-Fernandes et al. (2014), this cohort of
SCA-3 transgenic mice did not survive longer than
80 weeks after birth, an age at which all wild-type animals
were alive (Fig. 1C). SCA-3 transgenic mice gained
weight during the ﬁrst 3 months of age but, starting at
the age of 15 weeks after birth, they lost the capability
to gain weight compared to wild-type animals (Fig. 1D).
Later on, they exhibited weight loss that was noted ﬁrst
at the age of 39 weeks, but that prolonged up to the last
age recorded (55 weeks of age), a time-point in which
the weight of SCA-3 transgenic animals was a 65% of
the wild-type weight (Fig. 1D). At the age of 56 weeks,
SCA-3 transgenic mice were very debilitated showing,
together with the weight loss, an excessive curvature of
the spine called kyphosis, which was extremely marked
at such age (Fig. 1J), although it was already visible at
the age of 19 weeks (data not shown). The kyphosis could
be also visualized with the help of the computer-aided
tomography device at the age of 43 weeks (Fig. 1J) when
both wild-type and SCA-3 transgenic mice were subjected
to a PET analysis for quantifying glucose metabolism (see
below). This excessive curvature of the spine has been
observed in other SCA-3 murine models (Riess et al.,
2008; Gould, 2012).
SCA-3 transgenic mice exhibited highly signiﬁcant
deﬁcits that were initiated at the age of 11 weeks in the
hanging wire test, useful to detect muscle weakness
(Fig. 1E), and at the age of 15 weeks in the balance
beam, useful to detect deﬁcits in balance (Fig. 1F).These deﬁcits worsened progressively, in particular, the
hanging wire deﬁcits, up to the age of 31 weeks
(Fig. 1E and F), but the recording in these two tests had
to be stopped at this age as transgenic mice were
unable to perform at all. Deﬁcits in rotarod performance,
reﬂecting motor incoordination and also dystonia and
muscle weakness, appeared at older ages, speciﬁcally
at the age of 31 weeks but their intensity worsened up
to the age of 55 weeks (Fig. 1G). One week later,
animals were also examined for the presence of
hindlimb clasping, which is frequently used as a marker
of dystonia in a number of murine models of
neurological disorders, including certain cerebellar
ataxias (Chou et al., 2008). We found this response to
be extremely frequent in our SCA-3 transgenic mice, as
previously reported in other SCA-3 models (Gould,
2012), with values more than fourfold elevated
(Fig. 1H). The motor incoordination and imbalance
detected in SCA-3 transgenic mice were also evident in
the footprinting test, which reﬂects the animal gait, prov-
ing a completely disorganized performance (shorter
strides and loss of balance) for these animals (Fig. 1I).
Lastly, we also subjected our animals to in vivo positron
emission tomography (PET) analysis for determining the
regional glucose metabolism using 2-deoxy-2-[18F]
ﬂuoro-D-glucose ([18F]FDG) at two ages within the dis-
ease progression: 21 and 43 weeks after birth. We did
not ﬁnd any alteration in the early symptomatic age
(21 weeks), but we did ﬁnd a large reduction in
43-week-old animals in the whole brain and also in those
brain structures related to SCA-3 symptoms, e.g. cerebel-
lum, brainstem, caudate-putamen, and also in other corti-
cal and subcortical structures (Fig. 2). These results are in
agreement with the data described with the same proce-
dure in SCA-3 patients (Soong et al., 1997; Taniwaki
et al., 1997).
Next, we attempted to ﬁnd a neuropathological basis
for the above behavioral abnormalities, by analyzing
diﬀerent biochemical markers that reﬂect neuronal
malfunctioning, as well as by using histological
procedures to identify neuronal losses or glial activation.
We concentrated in two of the most-aﬀected structures
in SCA-3 in patients, i.e. cerebellum, brainstem (Murata
et al., 1998; Taroni and DiDonato, 2004; Koeppen,
2005; Riess et al., 2008), and, in some cases, we
included the analysis of the three selected ages repre-
senting the progression of the disease (16, 32 and
56 weeks), or we focused exclusively in the advanced
stage (56 weeks).
Most of the neuropathological analyses were
concentrated in the changes in the calcium-dependent
protein calbindin, which is frequently used as a marker
for Purkinje cells in the cerebellum (Ishikawa et al.,
1995). We did not ﬁnd any changes in calbindin gene
expression measured by qPCR in the three investigated
ages, and this was corroborated by similar analysis using
other neuronal markers such as neurons-speciﬁc enolase
(NSE) (frequently used for neurons of the dentate
nucleus; Nogami et al., 1998) and BDNF (Fig. 3A). In
addition, we did ﬁnd equivalent values for calbindin
immunostaining in the Purkinje cell layer in 56-week-old
0 20 40 60 80 100
0
50
100
150 wild-type SCA3
***
Age (weeks)
A
ni
m
al
 s
ur
vi
va
l (
%
)
wild-type SCA-3
0
200
400
600
***
C
la
sp
in
g 
(%
 o
ve
r w
ild
-ty
pe
)
7 11 15 19 23 27 31
0
20
40
60
80
wild-type SCA3
****
Age (weeks)
Ti
m
e 
in
 w
ire
 (s
)
A B 
Human 
ataxin-3 
Wild-type SCA-3 (at 56 weeks)  
Mouse 
ataxin-3 GAPDH 
polyQ 
Wild-type SCA-3 (at 56 weeks)  
C 
E F 
7 11 15 19 23 27 31
0
20
40
60
wild-type SCA3
**
*
Age (weeks)
Ti
m
e 
in
 b
ea
m
 (s
)
D 
Wild-type (at 56 weeks) SCA-3 (at 56 weeks)  
H G 
I 
Wild-type (at 56 weeks) 
SCA-3 (at 56 weeks)  
J Wild-type (at 56 weeks) SCA-3 (at 56 weeks)  
7 15 23 31 39 47 55
0
50
100
150
wild-type SCA3
* **
***
Age (weeks)
La
te
nc
y 
to
 fa
ll 
(s
)
7 15 23 31 39 47 55
15
20
25
30
35
40
45
wild-type SCA3
* **
***
Age (weeks)
W
ei
gh
t (
g)
Wild-type (at 43 weeks) SCA-3 (at 43 weeks)  
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mals (Fig. 3B), which is in agreement with previous data
obtained in patients that indicated a relative preservation
of these cells in SCA-3 (Gould, 2012). The same result
was, in general, obtained when calbindin levels were ana-
lyzed by western blot in the whole cerebellum of both
genotypes at 56 weeks after birth (Fig. 3C), although cer-
tain trend toward a decrease could be appreciated in
SCA-3 transgenic mice (Fig. 3C). This trend, seen when
the whole cerebellum was analyzed, possibly derives
from the reduction observed in calbindin immunostaining
in the dentate nucleus (Fig. 3D), a cerebellar area notably
aﬀected in this SCA-3 transgenic model (Silva-Fernandes
et al., 2014) and also in SCA-3 patients (Matilla-Duen˜as,
2012; Seidel et al., 2016). The analysis of this nucleuswith Nissl staining conﬁrmed that the number of stained
cells was signiﬁcantly reduced, whereas surviving neu-
rons showed a shrunken cell body, in 56-week-old SCA-
3 transgenic mice compared to wild-type animals
(Fig. 3E). These data are in agreement with losses in
the projecting neurons of the dentate nucleus as has been
seen in patients (Evert et al., 2006). The loss of calbindin
immunostaining in the dentate nucleus may also corre-
spond to axons of Purkinje cells that project to such
nucleus (Fig. 3D), and this could be related to the
grumose degeneration typically observed in SCAs
(Koeppen et al., 2013). As mentioned above, these
diﬀerences were not noted in the cell bodies of Purkinje
cells, when they were labeled with calbindin (Fig. 3B).
We also tried to label Purkinje cells with ubiquitin, which
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ataxin-3 aggregation, but we were unable to detect such
inclusions in these cells (data not shown), which, how-
ever, were evident in brainstem nuclei (see below). This
absence of ubiquitin-positive inclusions in the Purkinje
cells has been also described in other studies (Taroni
and DiDonato, 2004). On the other hand, we were unable
to detect any evidence of glial activation in the cerebellum
of SCA-3 transgenic mice compared to wild-type animals,
as revealed the similar values of gene expression seen for
the proinﬂammatory cytokines interleukin-1b (IL-1b) and
tumor necrosis factor-a (TNF-a) and for the glial
glutamate-aspartate transporter (GLAST) and glutamate
transporter-1 (GLT-1) at the three investigated ages
(Fig. 4A). This absence of gliosis was corroborated by
immunostaining with the microglial marker Iba-1, which
proved similar number of cells and immunoreactivity
levels in the cerebellar cortex and dentate nucleus of
56-week-old SCA-3 transgenic and wild-type mice
(Fig. 4B), a result also seen at earlier ages, 16 and
32 weeks after birth (data not shown). We also paid atten-
tion to the microglial morphology, which also reﬂects
microglial activation, and, whereas there were no diﬀer-ences at 16 and 32 weeks, we could appreciate some
changes at 56 weeks restricted to the dentate nucleus,
the only cerebellar area showing neuronal losses in
SCA-3 transgenic mice. These changes consisted in a
relative increase in the cell body size and a shortening
in their processes when compared to wild-type animals
(Fig. 4B). We also analyzed these structures with GFAP
immunostaining but we did not ﬁnd any diﬀerences
between SCA-3 transgenic and wild-type mice (data not
shown). This absence of gliosis in SCA-3 is not rare as
it has been previously found in other studies also working
with SCA-3 tissues (Ru¨b et al., 2013).
In addition, we were unable to reveal any signiﬁcant
diﬀerences in calbindin and NSE gene expression in the
brainstem of SCA-3 transgenic and wild-type mice at
the three investigated disease stages, always when the
whole brainstem was used for qPCR analysis (Fig. 5A).
This also happened with the analysis of BDNF gene
expression (Fig. 5A), despite reductions in the
expression of this neurotrophin have been found in this
structure in cellular models and post-mortem tissues of
SCA-3 patients (Evert et al., 2003). We also performed
Nissl staining of brainstem slices and found that the
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Fig. 3. Histological and biochemical analysis of neuronal injury in the cerebellum of SCA-3 transgenic and wild-type mice: Panel A: qPCR analysis
of calbindin, neuron-speciﬁc enolase, and BDNF in the cerebellum of SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression.
Panels B and D: Immunostaining for calbindin as a neuronal marker in the Purkinje cell layer (bar=200 lm and 50 lm, respectively), including
quantiﬁcation, and the dentate nucleus (bar=800 lm, 50 lm and 20 lm, respectively) of SCA-3 transgenic and wild-type mice at 56 weeks after
birth. Arrows indicate the location of calbindin-positive terminals in the dentate nucleus reﬂecting the low immunoreactivity seen in SCA-3 transgenic
mice. Panel C:Western blot quantiﬁcation (with a representative blot) of calbindin in the whole cerebellum of SCA-3 transgenic and wild-type mice at
56 weeks after birth. Panel E: Nissl staining and quantiﬁcation in the dentate nucleus of SCA-3 transgenic and wild-type mice at 56 weeks after birth
(bar=25 lm). Arrows indicate the presence of shrunken cell bodies in SCA-3 transgenic animals. In all cases, values are expressed as mean
± SEM of more than six subjects per group. Data were assessed by Student’s t-test (*p< 0.05 versus wild-type animals).
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is a highly-vulnerable brainstem structure in SCA-3
(Koeppen, 2005; Koeppen et al., 2013; Silva-Fernandes
et al., 2014), was signiﬁcantly reduced in 56-week-old
SCA-3 transgenic mice when compared to wild-type, with
notable changes in the morphology of remaining Nissl-
stained cells (Fig. 5B). This did not occur in another rele-
vant brainstem area such as the inferior olivary nucleus
(Fig. 5B). As mentioned above, we were able to detect
in this area positive ubiquitin immunostaining, which was
found in inclusions located in neurons of the pontine
nuclei and inferior olivary nucleus of 56-week-old SCA-3
transgenic mice (Fig. 5C), but not in wild-type tissues
(Silva-Fernandes et al., 2014). Such ubiquitin-positive
inclusions have been also found in patients and in other
models of SCA-3 (Paulson et al., 1997). The analysis of
glial activation in the whole brainstem revealed a statisti-cally signiﬁcant elevation in gene expression for TNF-a
and a trend toward an increase in IL-1b in SCA-3 trans-
genic mice but only at 56 weeks (Fig. 6A), a response
also found in SCA-3 patients (Evert et al., 2003, 2006).
This elevation of proinﬂammatory cytokines, which mainly
derive from microglial cells, was not associated with an
elevated immunoreactivity for the microglial marker Iba-
1 in the pontine nuclei of SCA-3 transgenic mice neither
at 56 weeks (Fig. 6B) nor at 16 and 32 weeks after birth
(data not shown). However, as in the cerebellum, we paid
attention to the microglial morphology and again, whereas
there was no diﬀerences at 16 and 32 weeks, we could
appreciate an apparent increase in the cell body size
and a shortening in the processes of microglial cells in
the pontine nuclei of SCA-3 transgenic mice when com-
pared to wild-type animals at 56 weeks (Fig. 6B). We also
measured glutamate transporters which, due to their
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Fig. 4. Histological and biochemical analysis of glial activation in the cerebellum of SCA-3 transgenic and wild-type mice: Panel A: qPCR analysis of
the proinﬂammatory cytokines IL-1b and TNF-a, and the glial glutamate transporters GLAST and GLT-1, in the cerebellum of SCA-3 transgenic and
wild-type mice at diﬀerent ages in disease progression. Panel B: Immunostaining for Iba-1 as a microglial marker in the cerebellar cortex and the
dentate nucleus of SCA-3 transgenic and wild-type mice at 56 weeks after birth (bar=200 lm, 50 lm and 10 lm, respectively). Arrows indicate the
presence of microglial cells with altered morphology (increased cell body and shorter processes) in the dentate nucleus of SCA-3 transgenic mice.
In all cases, values are expressed as mean ± SEM of more than six subjects per group. Data were assessed by Student’s t-test.
200 C. Rodrı´guez-Cueto et al. / Neuroscience 339 (2016) 191–209preferential location in astroglial cells, may be used as an
index of the activity of these cells. We found the gene
expression for GLT-1 to be reduced at 32 and 56 weeks,
with GLAST reduced only at 56 weeks (Fig. 6A). How-
ever, these responses were not associated with changes
in the immunostaining for the astrocyte marker GFAP in
brainstem structures of SCA-3 transgenic mice compared
to wild-type animals (data not shown).Analysis of the endocannabinoid signaling system in
the cerebellum of SCA-3 transgenic mice
The main objective of this study was to determine whether
the endocannabinoid signaling system becomes
dysregulated in the most-aﬀected CNS structures of
SCA-3 transgenic mice, so that this dysregulation may
be pharmacologically corrected with beneﬁts for disease
symptoms and progression, or, alternatively, the
potential changes may be enhanced in the case they
represent an adaptive response aimed at restoring celland tissue homeostasis as found in other
neurodegenerative disorders (Di Marzo et al., 2015). We
concentrated in six key endocannabinoid elements, the
CB1 and CB2 receptors, the two synthesizing enzymes,
N-arachidonoylphosphatidylethanolamine-phospholipase
D (NAPE-PLD) and diacylglycerol lipase (DAGL), and the
two hydrolyzing enzymes, FAAH and MAGL, which were
ﬁrst analyzed by qPCR in the three stages stated before,
and, upon the expectation of signiﬁcant changes, we
completed the analysis using western blot and immunos-
taining. The changes only occurred for the CB1 receptor
and the FAAH enzyme. We also carried out analysis of
endocannabinoids and related signaling lipids at the three
investigated stages.
The ﬁrst CNS structure investigated was the
cerebellum. We ﬁrst analyzed the expression of the CB1
receptor by qPCR, but we did not detect any diﬀerence
between SCA-3 transgenic and wild-type mice at the
three investigated stages (Fig. 7A). However, the
Western blot analysis of this structure at the age of
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Fig. 5. Histological and biochemical analysis of neuronal injury in the brainstem of SCA-3 transgenic and wild-type mice: Panel A: qPCR analysis of
calbindin, neuron-speciﬁc enolase, and BDNF in the brainstem of SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression.
Panel B: Nissl staining and quantiﬁcation in the pontine nuclei and inferior olivary nucleus of SCA-3 transgenic and wild-type mice at 56 weeks after
birth (bar=25 lm). Arrows indicate the presence of shrunken cell bodies in SCA-3 transgenic mice. Panel C: Immunostaining for ubiquitin (indicated
by arrows) in the pontine nuclei and inferior olivary nucleus of SCA-3 transgenic mice at 56 weeks after birth (bar=20 lm). In all cases, values are
expressed as mean ± SEM of more than six subjects per group. Data were assessed by Student’s t-test (*p < 0.05 versus wild-type animals).
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levels (Fig. 7B), which presumably reﬂected the
increase in CB1 receptor immunostaining seen in the
cerebellar cortex and, in particular, the Purkinje cell
layer at this stage (Fig. 7C), but not at earlier phases
(data not shown). The increase in the Purkinje cell layer
was most visible in the so-called pinceau formations
which correspond to the basket cell terminals contacting
the Purkinje cells (Sua´rez et al., 2008) (Fig. 7C). By con-
trast, we did not see a similar increase in CB1 receptor
immunostaining in the granular layer or in the dentate
nucleus (in this nucleus, the immunoreactivity was seen
in projecting neurons and in ﬁbers surrounding the cell
bodies of such projecting neurons) in 56-week-old SCA-
3 transgenic mice (Fig. 7C) or in earlier stages (data not
shown). In fact, CB1 receptor immunoreactivity in the den-
tate nucleus appeared to be lower in SCA-3 transgenicmice, presumably due to the neuronal losses seen in this
nucleus and discussed before.
Next, we measured FAAH enzyme and we detected
an increase in its gene expression in SCA-3 transgenic
mice at 16 weeks but not at older ages (Fig. 8A), which
was paralleled by trends toward an increase in FAAH
protein levels at 16 and 32 weeks after birth (Fig. 8B).
Immunostaining for this enzyme in the Purkinje cell layer
revealed the presence of FAAH in the Purkinje cells, as
happened in the human samples (Rodrı´guez-Cueto
et al., 2014b), but, also as happened in the samples from
SCA patients (Rodrı´guez-Cueto et al., 2014b), the stain-
ing pattern in SCA-3 transgenic mice was diﬀerent when
compared to wild-type animals. In these animals, the
immunoreactivity was located in the periphery of the cell
body as described in previous studies (Romero et al.,
2002), whereas it occupied the whole-cell body and was
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Fig. 6. Histological and biochemical analysis of glial activation in the brainstem of SCA-3 transgenic and wild-type mice: Panel A: qPCR analysis of
the proinﬂammatory cytokines IL-1b and TNF-a, and the glial glutamate transporters GLAST and GLT-1, in the brainstem of SCA-3 transgenic and
wild-type mice at diﬀerent ages in disease progression. Panel B: Immunostaining for Iba-1 as a microglial marker in the pontine nuclei of SCA-3
transgenic and wild-type mice at 56 weeks after birth (bar=200 lm, 50 lm and 20 lm, respectively). Arrows indicate the presence of microglial cells
with altered morphology (increased cell body and shorter processes) in the pontine nuclei of SCA-3 transgenic mice. In all cases, values are
expressed as mean ± SEM of more than six subjects per group. Data were assessed by Student’s t-test (*p< 0.05, **p< 0.01, ***p< 0.005 versus
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this was strongly evident at 16 and 32 weeks, but to a les-
ser extent at 56 weeks (Fig. 8C). Such response also
occurred in other cerebellar areas such as the white mat-
ter (Fig. 8D), but not in the dentate nucleus (data not
shown). We also monitored the changes in other endo-
cannabinoid genes, e.g. CB2 receptor, NAPE-PLD, DAGL
and MAGL, along the three investigated stages, but we
did not detect any diﬀerence between SCA-3 transgenic
and wild-type mice (Fig. 9A–D). The lack of changes in
CB2 receptors was in agreement with the absence of an
important reactive gliosis, hence we discarded to further
explore this receptor using immunostaining procedures.
We also measured the levels of anandamide and
2-arachidonoylglycerol (2-AG), as well as their related sig-
naling lipids palmitoylethanolamide (PEA), oleylethanola-
mide (OEA) and 2-oleylglycerol (2-OG), but they were
similar in SCA-3 transgenic and wild-type mice in the
three investigated disease stages (Fig. 9E–I).
Analysis of the endocannabinoid signaling system in
the brainstem of SCA-3 transgenic mice
We also analyzed gene expression for the CB1 receptor in
the whole brainstem, but we did not ﬁnd any diﬀerences in
the three stages investigated (Fig. 10A), which correlated
with equivalent immunoreactivity for this receptor in the
pontine nuclei also at the three ages investigated
(Fig. 10B). In this nucleus, the immunoreactivity was
detected both in cell bodies and ﬁbers, as previously
described (Cristino et al., 2006; Sua´rez et al., 2008).
Again, we next concentrated in FAAH enzyme whose
gene expression in the whole brainstem did not vary along
the disease progression (Fig. 10C). However, FAAH
levels measured by Western blotting tended toward an
increase at 16 weeks which reached statisticalsigniﬁcance at 32 weeks in SCA-3 transgenic mice,
although the diﬀerences disappeared at the advanced
stage (56 weeks) (Fig. 10D). These diﬀerences were
also evident using FAAH immunostaining, with
immunoreactivity located in ﬁbers and cell bodies that
appeared to be much more marked in SCA-3 transgenic
mice (Fig. 10E). This happened in diﬀerent areas of the
brainstem and it was particularly evident in the early and
intermediate phases of the disease, with the pontine
nuclei as the most relevant structure (Fig. 10E). We
also measured the expression of other endocannabinoid
genes, e.g. CB2 receptor, NAPE-PLD, DAGL and
MAGL, along the three investigated stages, but again
we did not detect any diﬀerence between SCA-3
transgenic and wild-type mice despite certain trends
toward an increase seen for MAGL enzyme at 32 and
56 weeks (Fig. 11A–D). Lastly, we measured the levels
of endocannabinoids, and related N-acylethanolamines
and 2-acylglycerols, and, in this case, we did ﬁnd
reductions in anandamide levels at 32 weeks (Fig. 11E),
and in OEA levels at 16 and 32 weeks, and a trend
toward a decrease at 56 weeks (Fig. 11H), which
correlates well with the increase in FAAH enzyme
indicated before (Fig. 10D–E). No changes were seen in
brainstem levels of 2-AG (Fig. 11F), PEA (Fig. 11G) and
2-OG (Fig. 11I).
DISCUSSION
The data published by Silva-Fernandes et al. (2014),
together with the additional neurological and
neuropathological characterization carried out here in
their SCA-3 transgenic mice, provide a solid evidence to
consider this mouse model as a useful tool to investigate
this human pathology. These mice exhibit a relatively slow
disease progression, as in humans, living for more than
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of motor anomalies comparable to the clinical symptoms
found in patients, which are the consequence of selective
degeneration in neurons located in the cerebellum (den-
tate nucleus) and brainstem (pontine nuclei), which are
all also aﬀected in the human pathology (Koeppen,
2005; Matilla-Duen˜as, 2012; Koeppen et al., 2013;
Seidel et al., 2016). Also as found in humans, neurode-
generation does not appear to be associated with very
marked glial activation and inﬂammatory events (Ru¨b
et al., 2013). Nevertheless, there is an early alteration of
glial glutamate transporters, which relates the degenera-
tive process to excitotoxicity in the brainstem, but not in
the cerebellum. This has been also found in other SCA-
3 models (Chou et al., 2008) and has been claimed by
some authors as the basis for understanding the exten-
sion of neurodegeneration in SCA-3 to extracerebellar
structures (Seidel et al., 2012). All this evidence supportthat this can be a useful model for the study of SCA-3 pro-
gression, including the contribution of the endocannabi-
noid signaling system to this progression, the objective
pursued in this study, as well as for future preclinical stud-
ies with potential neuroprotective compounds, including
also those acting at the diﬀerent endocannabinoid targets.
Our study addressed for the ﬁrst time the changes in
the endocannabinoid signaling in the CNS of a
murine model of SCA-3. As we have already mentioned,
this is a necessary step in the development of a
cannabinoid-based therapy for delaying the progression
of the SCA-3-like pathological phenotype. Our idea was
to investigate whether the endocannabinoid signaling
becomes dysregulated in key CNS structures in these
mice, and we conﬁrmed that this is the case, as our
ﬁndings are consistent with: (i) an elevated CB1
receptor signaling in the Purkinje cell layer, and the
opposite in the dentate nucleus, in the cerebellum; and
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endocannabinoids in the pontine nuclei of the brainstem.
The occurrence of such dysregulated endocannabinoid
signals are clearly dependent on cellular context, as
they are not similar in the two structures investigated,
and they can have some important consequences which
will be addressed with more detail below.
First, endocannabinoid dysregulation may contribute
to speciﬁc aspects of the pathogenesis, for example,
loss of CB1 receptors may be related to excitotoxicity,
given the role of this receptor in controlling glutamate
homeostasis (Ferna´ndez-Ruiz et al., 2015), then facilitat-
ing neuronal losses. This may be the case of CB1 recep-
tors in two key cerebellar areas: the Purkinje cell layer and
the dentate nucleus. Our data indicate that CB1 receptors
are preserved, and even elevated, in the Purkinje celllayer, which correlated with no losses of Purkinje cells
and other neuronal subpopulations, whereas cell death
was evident in neurons of the dentate nucleus in parallel
to an apparent reduction in CB1 receptors in these neu-
rons and also in terminals contacting such neurons. Inter-
esting implications also derive from our observations
concerning FAAH, as we detected an elevation of this
enzyme in certain brainstem nuclei in parallel to reduced
levels of endocannabinoids, which may possibly diminish
the capability of these signaling lipids to exert their protec-
tive role on cellular homeostasis, then facilitating the neu-
ronal losses found in some structures such as the pontine
nuclei.
Second, the changes in the endocannabinoid
signaling may be also associated with the appearance
of speciﬁc neurological symptoms in SCA-3 transgenic
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Fig. 9. Biochemical analysis of endocannabinoid genes, and levels of endocannabinoids and related signaling lipids in the cerebellum of SCA-3
transgenic and wild-type mice: Panels A–D: qPCR analysis of the CB2 receptor and the NAPE-PLD, DAGL and MAGL enzymes in the cerebellum of
SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression. Panels E–I: LC-MS analysis of the levels of anandamide (AEA) and
its related congeners palmitoylethanolamide (PEA) and oleylethanolamide (OEA), as well as 2-arachidonoylglycerol (2-AG) and its congener
2-oleylglycerol (2-OG) in the cerebellum of SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression. In all cases, values are
expressed as mean ± SEM of 5–6 subjects per group. Data were assessed by Student’s t-test.
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signaling has been associated with the occurrence of
cerebellum-related symptoms like limb ataxia in naı¨ve
animals in previous pharmacological studies (DeSanty
and Dar, 2001; Patel and Hillard, 2001). A similar conclu-
sion emerged from the studies relating mutations in
ABHD12 with the occurrence of ataxia (Fiskerstrand
et al., 2010; Chen et al., 2013), as it is expected that
loss-of-function mutations in this enzyme should elevate
2-AG levels in the CNS (at least in those areas having
lower MAGL activity), which, through an excess of CB1
receptor activation, could explain the appearance of atax-
ia. These data have been reproduced in mice with genetic
ablation of ABHD12 (Blankman et al., 2013). Therefore,
we assume that the elevation of CB1 receptors we found
in the Purkinje cell layer of SCA-3 transgenic mice, pre-
dominantly in terminals of the basket cells, may also have
an inﬂuence in the occurrence of ataxia, independently of
the role of this receptor in slowdown the progression of
the disease. It is also interesting to mention a recent studyby Wang et al. (2013), who described a deﬁcient CB1
receptor signaling in a murine model of ataxia generated
by mutations in the a2d2 subunit of the voltage-
dependent calcium channel, which mainly aﬀected the
Purkinje cells. However, this murine model may be more
reminiscent of SCA-6, which is the SCA type with greater
deterioration of Purkinje cells, derived from the naturally-
occurring mutation in the a1A subunit of the same
channel.
Lastly, the relevance of the abovementioned changes
in speciﬁc endocannabinoid elements for either disease
progression or speciﬁc symptoms, is that they may
be possibly corrected by diﬀerent pharmacological
approaches. One possibility is to develop therapies for
alleviating speciﬁc symptoms, for example, to reduce
ataxia by blocking the elevated CB1 receptors found in
the Purkinje cell layer. Previous pharmacological
studies support these potential beneﬁts on speciﬁc
symptoms (DeSanty and Dar, 2001; Patel and Hillard,
2001; Stephens, 2016). However, as found in other
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Fig. 10. Histological and biochemical analysis of the CB1 receptor and the FAAH enzyme in the brainstem of SCA-3 transgenic and wild-type mice:
Panel A: qPCR analysis of the CB1 receptor in the brainstem of SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression. Panel
B: Immunostaining for the CB1 receptor in the pontine nuclei of SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression
(bar=50 lm). Panels C and D: qPCR analysis and Western blot quantiﬁcation (with a representative blot) of the FAAH enzyme in the brainstem of
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206 C. Rodrı´guez-Cueto et al. / Neuroscience 339 (2016) 191–209neurodegenerative disorders, e.g. Parkinson’s disease
(Ferna´ndez-Ruiz et al., 2011), the best option to get
an eﬀective and sustained symptom relief with
cannabinoid-based therapies is the control of disease
progression, something for which cannabinoids are par-
ticularly enabled (Ferna´ndez-Ruiz et al., 2015). In this
sense, our data support that the activation of CB1 recep-
tors may be beneﬁcial for preserving the neurons of the
dentate nucleus, whose CB1 receptor signaling is ham-
pered. Such therapy would be aimed at correcting the
dysregulation of endocannabinoid signaling by enhancing
CB1 receptor function, assuming that the dysregulation
represents a maladaptive response that contributes to
disease progression. This may be also the case of ele-
vated FAAH-mediated hydrolysis of endocannabinoids
found in some brainstem nuclei, which would be also a
maladaptive response contributing to disease progres-sion. The option in this case may be to selectively inhibit
FAAH enzyme with the purpose of enhancing the levels
of endocannabinoids and their protective function. In both
cases, enhancing CB1 receptor signaling or inhibiting
FAAH enzyme would be addressed to correct the
changes in both targets that are contributing to
pathogenesis. However, the neuroprotective properties
derived from the manipulation of the endocannabinoid
signaling may also include to enhance speciﬁc responses
of this signaling that represent adaptive mechanisms
aimed at restoring neuronal homeostasis against diﬀerent
damaging stimuli (Di Marzo et al., 2015). We expected
this may be the case of CB2 receptor-mediated signaling,
given that up-regulatory responses aimed at preserving
neurons against inﬂammatory events have been
identiﬁed for most of neurodegenerative disorders
(Ferna´ndez-Ruiz et al., 2007, 2010, 2011) including
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Fig. 11. Biochemical analysis of endocannabinoid genes, and levels of endocannabinoids and related signaling lipids in the brainstem of SCA-3
transgenic and wild-type mice: Panels A–D: qPCR analysis of the CB2 receptor and the NAPE-PLD, DAGL and MAGL enzymes in the brainstem of
SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression. Panels E–I: LC-MS analysis of the levels of anandamide (AEA) and
its related congeners palmitoylethanolamide (PEA) and oleylethanolamide (OEA), as well as 2-arachidonoylglycerol (2-AG) and its congener
2-oleylglycerol (2-OG) in the brainstem of SCA-3 transgenic and wild-type mice at diﬀerent ages in disease progression. In all cases, values are
expressed as mean ± SEM of 5–6 subjects per group. Data were assessed by Student’s t-test (*p< 0.05, **p< 0.01 versus wild-type animals).
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patients (Rodrı´guez-Cueto et al., 2014a). We had also
considered the interest of a speciﬁc interaction of the
CB2 receptor with the heat shock protein 90 (Hsp90),
as has been recently found in eye cells (He et al.,
2012), given that inhibition of this molecular chaperone
has been found to be beneﬁcial in SCA-3 transgenic mice
(Silva-Fernandes et al., 2014). However, we were unable
to ﬁnd any evidence of CB2 receptor up-regulation in the
two highly vulnerable areas investigated in these SCA-3
transgenic mice, in which the levels of CB2 receptors
remained permanently unaﬀected. As mentioned above,
it is possible that the lack of response of the CB2 receptor
derives from the absence of reactive gliosis in these
areas, a fact that had been already described in this
model (Silva-Fernandes et al., 2014). Another adaptive
response frequently elicited by the endocannabinoid
signaling in response to damage is the elevation in thegeneration of endocannabinoids. This has been found
in numerous chronic neurodegenerative disorders
(Ferna´ndez-Ruiz et al., 2010) and our study represented
the ﬁrst time that the levels of these signaling lipids were
analyzed in SCA-3 tissues. However, we were unable to
demonstrate that endocannabinoid levels are signiﬁcantly
elevated in the brain of SCA-3 transgenic mice. Indeed,
the only change we were able to detect was a reduction
in the brainstem which, as mentioned above, possibly
derived from an increased degradation by the elevated
FAAH levels in this structure, then contributing to disease
progression rather than being an adaptive protective
response.CONCLUSIONS
Our results in SCA-3 mutant mice conﬁrm a possible
dysregulation in the endocannabinoid signaling system
208 C. Rodrı´guez-Cueto et al. / Neuroscience 339 (2016) 191–209in the most important brain structures aﬀected in this type
of ataxia, suggesting that a pharmacological manipulation
addressed to correct the changes in the endocannabinoid
signaling could be a promising option in SCA-3. We are
presently conducting pharmacological experiments to
validate this hypothesis.STATEMENT OF COMPETING INTEREST
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